Abstract:CLINICAL QUESTION What is the role of drug interventions in the treatment and prevention of covid-19? RECOMMENDATIONS The first version on this living guidance focuses on corticosteroids. It contains a strong recommendation for systemic corticosteroids in patients with severe and critical covid-19, and a weak or conditional recommendation against systemic corticosteroids in patients with non-severe covid-19. Corticosteroids are inexpensive and are on the World Health Organisation list of essential medicines. HOW this guideline was created This guideline reflects an innovative collaboration between the WHO and the MAGIC Evidence Ecosystem Foundation, driven byan urgent need for global collaboration to provide trustworthy and living covid-19 guidance. A standing international panel of content experts, patients, clinicians, and methodologists, free from relevant conflicts of interest, produce recommendations for clinical practice. The panel follows standards, methods, processes, and platforms for trustworthy guideline development using the GRADE approach. We apply an individual patient perspective while considering contextual factors (that is, resources, feasibility, acceptability, equity) for countries and healthcare systems. THE EVIDENCE A living systematic review and network meta-analysis, supported by a prospective meta-analysis, with data from eight randomised trials (7184 participants) found that systemic corticosteroids probably reduce 28 day mortality in patients with critical covid-19 (moderate certainty evidence; 87 fewer deaths per 1000 patients (95% confidence interval 124 fewer to 41 fewer)), and also in those with severe disease (moderate certainty evidence; 67 fewer deaths per 1000 patients (100 fewer to 27 fewer)). In contrast, systemic corticosteroids may increase the risk of death in patients without severe covid-19 (low certainty evidence; absolute effect estimate 39 more per 1000 patients, (12 fewer to 107 more)). Systemic corticosteroids probably reduce the need for invasive mechanical ventilation, and harms are likely to be minor (indirect evidence). UNDERSTANDING THE RECOMMENDATIONS The panel made a strong recommendation for use of corticosteroids in severe and critical covid-19 because there is a lower risk of death among people treated with systemic corticosteroids (moderate certainty evidence), and they believe that all or almost all fully informed patients with severe and critical covid-19 would choose this treatment. In contrast, the panel concluded that patients with non-severe covid-19 would decline this treatment because they would be unlikely to benefit and may be harmed. Moreover, taking both a public health anda patient perspective, the panel warned that indiscriminate use of any therapy for covid-19 would potentially rapidly deplete global resources and deprive patients who may benefit from it most as potentially lifesaving therapy. UPDATES This isa living guideline. Work is under way to evaluate other interventions. New recommendations will be published as updates to this guideline. READERS NOTE This is version 1 of the living guideline, published on 4 September (BMJ 2020;370:m3379) version 1. Updates will be labelled as version 2, 3 etc. When citing this article, please cite the version number. SUBMITTED August 28 ACCEPTED August 31 As of 1 September 2020, 25 327 098 people worldwide have been diagnosed with covid-19, according to the international World Health Organization (WHO) dashboard. 1 The pandemic has claimed 848 255 lives, and a resurgence in the number of new cases and continued growth is some countries has threatened high resource and low resource countries alike.

Adaptation of WHO COVID-19 guidelines by Caribbean countries and territories

Variations in Processes for Guideline Adaptation: a Qualitative Study of World Health Organization Staff Experiences in Implementing Guidelines

"I think they should give primary health care a little more priority". The primary health care in Caribbean SIDS: what can be said about adaptation to the changing climate? The case of Dominica- a qualitative study

Intersectoral collaboration in the COVID-19 response in Latin America and the Caribbean

Getting trustworthy guidelines into the hands of decision-makers and supporting their consideration of contextual factors for implementation globally: recommendation mapping of COVID-19 guidelines

A Living WHO Guideline on Drugs for Covid-19 (vol 370, M3379, 2020)

Health system adaptions to improve care for people living with non-communicable diseases during COVID-19 in low-middle income countries: A scoping review

Readiness of primary care centres for a community-based intervention to prevent and control noncommunicable diseases in the Caribbean: A participatory, mixed-methods study

Disruption of diabetes and hypertension care during the COVID-19 pandemic and recovery approaches in the Latin America and Caribbean region: a scoping review protocol

Assessment of the Functional Capacity and Preparedness of the Haitian Healthcare System to Fight against the COVID-19 Pandemic: A Narrative Review

Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context

A living WHO guideline on drugs to prevent covid-19

Pharmacovigilance in the Caribbean Countries: an Overview

Building sustainable capacity to adopt, adapt or develop child health guidelines, Malawi, Nigeria and South Africa

Strengthening guideline contextualization in the WHO European Region

Adapting medical guidelines to be patient-centered using a patient-driven process for individuals with sickle cell disease and their caregivers

Barriers to and facilitators of living guidelines use in low-income and middle-income countries: a scoping review

Clinical practice guidelines: Their utility, dissemination and monitoring at Colonial War Memorial Hospital: A mixed methods study from Fiji

Pan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API)

International alliance and AGREE-ment of 71 clinical practice guidelines on the management of critical care patients with COVID-19: a living systematic review

2021 World Health Organization guideline on pharmacological treatment of hypertension: Policy implications for the region of the Americas